Supplementary data B Any reported adverse event that occurred in less than 5% of any group – grouped under the primary System Organ Class, according to the MedDRA coding system.
This dataset contains the minimal underlying data used to reproduce the findings of the study titled “Safety profile of fondaparinux based on the FAERS database: a disproportionality analysis”. The da
*Adverse events leading to study drug discontinuation: Immediate Switch: emergent to EFV/FTC/TDF—anxiety; insomnia; night sweatsDelayed Switch: emergent to ABC/3TC + EFV (baseline to Wk12)—depressionD
